0001610717-24-000349.txt : 20240620
0001610717-24-000349.hdr.sgml : 20240620
20240620161148
ACCESSION NUMBER: 0001610717-24-000349
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240617
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelsey Stephen Michael
CENTRAL INDEX KEY: 0001462808
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39219
FILM NUMBER: 241056338
MAIL ADDRESS:
STREET 1: C/O GERON CORPORATION
STREET 2: 230 CONSTITUTION DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revolution Medicines, Inc.
CENTRAL INDEX KEY: 0001628171
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472029180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 415-766-3638
MAIL ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
form4.xml
X0508
4
2024-06-17
0001628171
Revolution Medicines, Inc.
RVMD
0001462808
Kelsey Stephen Michael
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
REDWOOD CITY
CA
94063
true
See Remarks
true
Common Stock
2024-06-17
4
S
0
3349
37.387
D
269073
D
Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
This transaction was executed in multiple trades in prices ranging from $37.3867 to $37.3887, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024.
Includes 95,476 RSUs.
President, Research and Development
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
2024-06-20